Profile data is unavailable for this security.
About the company
Heidelberg Pharma AG, formerly Wilex AG, is a Germany-based Company, which is engaged in the biopharmaceuticals sector. The Company focuses on the research and development of therapy treatments for oncology area. It aims at applying toxin Amanitin into cancer therapies using its Antibody Targeted Amanitin Conjugate (ATAC) technology. The Company’s pipeline includes a number of drug candidates, such as HDP-101, a B-cell maturation antigen ATAC for multiple myeloma; PSMA-ATAC, prostate-specific membrane antigens, and CD19-ATAC, a B-lymphocyte antigen. Through partnerships, the Company develops clinical assets, including MESUPRON, REDECTANE and RENCAREX. It also offers preclinical contract research services.
- Revenue in EUR (TTM)9.52m
- Net income in EUR-13.06m
- Incorporated2017
- Employees97.00
- LocationHeidelberg Pharma AGSchriesheimer Strasse 101LADENBURG 68526GermanyDEU
- Phone+49 620310090
- Fax+49 6 203100919
- Websitehttps://www.heidelberg-pharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adocia SA | 2.15m | -21.16m | 85.30m | 78.00 | -- | -- | -- | 39.67 | -1.93 | -1.93 | 0.194 | -0.4908 | 0.0774 | 2.62 | 7.44 | 27,564.10 | -76.16 | -43.08 | -396.14 | -72.93 | 7.91 | -- | -984.28 | -514.53 | 1.01 | -2.07 | 2.12 | -- | -81.22 | -46.13 | -206.65 | -- | -27.60 | -- |
| Alligator Bioscience AB | 4.02m | -20.63m | 88.24m | 51.00 | -- | -- | -- | 21.93 | -0.362 | -0.362 | 0.0696 | -0.0125 | 0.2653 | -- | 9.47 | 788,034.50 | -136.02 | -73.26 | -367.94 | -91.33 | -- | -- | -512.61 | -811.68 | -- | -35.61 | 5.17 | -- | 62.78 | 16.60 | -28.53 | -- | -20.34 | -- |
| Inventiva SA | 17.48m | -110.43m | 94.46m | 112.00 | -- | -- | -- | 5.40 | -2.45 | -2.45 | 0.3854 | -0.6146 | 0.1884 | -- | 9.18 | 156,044.60 | -116.84 | -54.30 | -207.08 | -69.98 | -- | -- | -620.31 | -669.97 | 0.9524 | -19.98 | 6.96 | -- | 43.50 | 40.46 | -103.46 | -- | -0.33 | -- |
| Anatolia TaniveBytklj Unli Ar Ge SiveTiA | 8.02m | -5.48m | 96.32m | 229.00 | -- | 2.79 | -- | 12.01 | -0.5563 | -0.5563 | 1.85 | 5.98 | 0.2549 | 0.3473 | 4.29 | 1,490,227.00 | -17.42 | 16.60 | -18.36 | 17.72 | 80.55 | 85.88 | -68.34 | 39.69 | 5.78 | -- | 0.0142 | -- | -49.14 | 72.60 | -548.82 | -- | 65.06 | -- |
| Maat Pharma SA | 2.23m | -19.72m | 102.16m | 50.00 | -- | 4.17 | -- | 45.85 | -1.73 | -1.73 | 0.196 | 1.76 | 0.0508 | 4.84 | 4.16 | 44,560.00 | -44.99 | -35.49 | -58.93 | -42.98 | 74.28 | -- | -884.96 | -1,157.54 | 2.76 | -49.61 | 0.4075 | -- | 55.80 | -- | -43.78 | -- | 30.30 | -- |
| Scope Fluidics SA | 21.78k | -5.29m | 104.71m | 40.00 | -- | 6.03 | -- | 4,807.02 | -8.29 | -8.29 | 0.0341 | 27.18 | 0.0009 | 2.94 | 0.0337 | 2,325.00 | -21.76 | 52.74 | -22.74 | 57.32 | -2,022.58 | -420.87 | -24,304.30 | 30,134.78 | 13.86 | -- | 0.0299 | -- | 27.72 | -- | -105.76 | -- | 89.99 | -- |
| Eurofins-Cerep SA | 44.07m | 7.64m | 107.94m | 228.00 | 14.13 | 1.67 | 11.23 | 2.45 | 1,514.43 | 1,514.43 | 8,743.94 | 12,820.37 | 0.5864 | 1.67 | 5.08 | 193,287.10 | 10.16 | 14.21 | 12.22 | 17.51 | 85.01 | 73.61 | 17.33 | 19.77 | 4.87 | -- | 0.00005 | -- | -7.47 | 11.60 | -33.72 | 14.64 | -- | -- |
| Heidelberg Pharma AG | 9.52m | -13.06m | 109.52m | 97.00 | -- | 2.66 | -- | 11.50 | -0.2837 | -0.2837 | 0.2062 | 0.8832 | 0.1270 | 0.194 | 13.23 | 100,234.60 | -17.42 | -43.91 | -22.34 | -64.34 | 82.74 | 52.13 | -137.16 | -206.24 | 4.90 | -- | 0.3417 | -- | -46.75 | 21.87 | -3.27 | -- | -0.8341 | -- |
| BenevolentAI SA | 5.81m | -61.35m | 111.26m | 248.00 | -- | 1.13 | -- | 19.15 | -0.5111 | -0.5111 | 0.0484 | 0.6886 | 0.0401 | -- | 0.1712 | 23,425.98 | -42.37 | -- | -50.50 | -- | -14.73 | -- | -1,056.02 | -- | -- | -- | 0.0594 | -- | -30.58 | -- | 61.38 | -- | -- | -- |
| Egetis Therapeutics AB (publ) | 8.27m | -26.10m | 118.25m | 32.00 | -- | 3.34 | -- | 14.30 | -1.23 | -1.23 | 0.3884 | 1.37 | 0.1496 | 13.45 | 7.48 | 3,477,778.00 | -33.65 | -33.02 | -40.07 | -36.46 | 92.12 | -- | -224.92 | -357.72 | 1.55 | -24.39 | 0.2158 | -- | 154.87 | 15.35 | -68.68 | -- | -- | -- |
| XSpray Pharma AB (publ) | 0.00 | -18.91m | 118.76m | 26.00 | -- | 2.48 | -- | -- | -7.05 | -7.05 | 0.00 | 19.79 | 0.00 | -- | -- | 0.00 | -33.11 | -18.38 | -36.76 | -19.26 | -- | -- | -- | -- | 3.50 | -- | 0.0496 | -- | -- | -- | -36.45 | -- | 2.87 | -- |
| Oryzon Genomics SA | 0.00 | -3.82m | 119.24m | 43.00 | -- | 1.34 | -- | -- | -0.0597 | -0.0597 | 0.00 | 1.37 | 0.00 | 153.65 | -- | 0.00 | -3.55 | -4.20 | -4.13 | -4.82 | -- | -- | -- | -- | 0.9495 | -3.54 | 0.134 | -- | -- | -- | 20.76 | -- | 15.52 | -- |
| Diamyd Medical AB | 16.38k | -12.29m | 123.46m | 25.00 | -- | 7.39 | -- | 7,537.94 | -1.55 | -1.55 | 0.0021 | 1.96 | 0.0009 | -- | 3.35 | 7,440.00 | -68.99 | -25.46 | -76.65 | -28.37 | -7,386.02 | -1,419.23 | -75,065.59 | -5,896.43 | -- | -90.74 | 0.1391 | -- | 20.26 | -5.54 | -12.13 | -- | -- | -- |
| Futura Medical PLC | 10.02m | -4.48m | 129.33m | 12.00 | -- | 13.88 | -- | 12.90 | -0.0126 | -0.0126 | 0.0272 | 0.0259 | 0.8538 | 5,710.27 | 7.20 | 699,850.80 | -38.14 | -79.25 | -47.43 | -127.22 | 67.70 | -- | -44.68 | -914.37 | 3.75 | -- | 0.00 | -- | -- | -- | -11.40 | -- | 219.68 | -- |
| Nightingale Health Oyj | 3.65m | -18.06m | 133.33m | 81.00 | -- | 2.22 | -- | 36.49 | -0.2979 | -0.2979 | 0.0603 | 1.50 | 0.0344 | 1.60 | 3.87 | 44,560.98 | -17.02 | -14.20 | -18.12 | -15.69 | 75.81 | 83.57 | -494.25 | -408.50 | 14.15 | -- | 0.0378 | -- | 80.80 | 19.05 | -12.38 | -- | -- | -- |
Data as of Sep 20 2024. Currency figures normalised to Heidelberg Pharma AG's reporting currency: Euro EUR
1.04%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Universal-Investment-Gesellschaft mbH (Invt Mgmt)as of 28 Jun 2024 | 252.58k | 0.54% |
| Polar Capital LLPas of 28 Jun 2024 | 213.76k | 0.46% |
| Financi�re Arbevel SAas of 30 Dec 2022 | 13.40k | 0.03% |
| Gutmann Finanz Strategien AGas of 31 Mar 2024 | 3.40k | 0.01% |
| State Board of Administration of Florida Retirement Systemas of 30 Jun 2023 | 0.00 | 0.00% |
More ▼
Data from 31 Mar 2024 - 31 Jul 2024Source: FactSet Research Systems Inc.
